Subscribe (Free) to
Daily or Weekly Newsletters
Post a Job

Featured Jobs

Retirement Plan Service Representative

DeMars Pension Consulting Services, Inc.
(Overland Park KS / MO)

Retirement Plan Administrator

Aegis Retirement Partners
(Remote)

Aegis Retirement Partners logo

401k & Defined Contribution Plan Consultant

Planned Retirement Consultant & Administrators, LLC
(Remote / Ridgewood NJ)

Planned Retirement Consultant & Administrators, LLC logo

Manager, 403(b) Plan Operations

Pentegra
(Remote)

Pentegra logo

Defined Contribution Account Manager

Nova 401(k) Associates
(Remote)

Nova 401(k) Associates logo

Senior Defined Contribution Account Manager

Nova 401(k) Associates
(Remote)

Nova 401(k) Associates logo

Regional Vice President Sales - Southeast

The Retirement Plan Company
(Remote / AL / FL / GA / MS)

The Retirement Plan Company logo

View More Employee Benefits Jobs

Free Newsletters

“BenefitsLink continues to be the most valuable resource we have at the firm.”

-- An attorney subscriber

Mobile app icon
LinkedIn icon     Twitter icon     Facebook icon
Webinars
and Podcasts
  >  Upcoming   |   Recorded
Conferences
(In-Person or Virtual)
  >  Upcoming   |   Grouped by Location
All   >  Upcoming   |   Grouped by Sponsor

View More Segal Webinars, Podcasts and Conferences

New Drugs for Weight Loss: What Plan Sponsors Need to Know

Segal

May 24, 2023
Recorded Online
Webinar

The latest generation of prescription drugs originally developed to help people manage their type 2 diabetes, such as Ozempic®, have been causing quite a stir for patients, health professionals and benefit plans now that some have been both approved and promoted for treating obesity. The effectiveness of and demand for these newer drugs are prompting some plan sponsors that exclude anti-obesity drugs from coverage to revisit plan rules. However, there are concerns about the potentially large target patient population, as well as the increased utilization and the high cost of these drugs.

You’re invited to join a webinar that will address the range of issues plan sponsors face related to weight-loss benefits and potential coverage of newer anti-obesity drug therapies.

You’ll gain an understanding of

  • The history behind glucagon-like peptide-1 or GLP-1 medications and their on- and off-label use
  • How GLP-1 medication usage trends are impacting benefit plans
  • Ways to better manage the rising utilization and cost of GLP-1 medications
  • How federal laws like the Mental Health Parity and Addiction Equity Act affect coverage decisions
  • What to consider before deciding to cover anti-obesity medications, including the importance of incorporating behavioral health programs into your strategy

More Information, How to Register

© 2024 BenefitsLink.com, Inc.